Sharjah ruler promises to release 149 Indian prisoners

Bengaluru, Mar 13: Google said on Friday that an employee at its Bengaluru office has tested positive for the COVID-19 coronavirus and the firm has directed all its employees in that office to work from home today as a precautionary measure.

"We can confirm that an employee from our Bangalore office has been diagnosed with COVID-19. They were in one of our Bangalore offices for a few hours before developing any symptoms. The employee has been on quarantine since then," Google said in a statement.

The firm has asked colleagues who were in close contact with the employee to quarantine themselves and monitor their health.

"Out of an abundance of caution, we are asking employees in that Bangalore office to work from home on Friday. We have taken and will continue to take all necessary precautionary measures, following the advice of public health officials, as we prioritize everyone's health and safety," it added.

The World Health Organisation (WHO) has declared the coronavirus outbreak a pandemic.

Coronavirus, which originated in the Wuhan city of China, has so far spread to more than 100 countries infecting over 1,20,000 people. India has confirmed 73 cases of the lethal infection.

Mangaluru, Jan 3: Mangaluru police arrested another person on charge of spreading communal hatred through messages. The accused have been identified as Abubakkar Siddique (48).

"One Abubakkar Siddique has been arrested in connection with a case for spreading communal hatred through inciting messages," said Dr PS Harsha, commissioner of police, Mangaluru.

On December 31, Police have arrested one person, Moideen Hameez, on charge of spreading communal hatred through social media.

The Mangaluru city police on Monday served notices to a few persons for posting inflammatory messages on social media.

The Cyber Crime police have summoned the accused persons to appear before it on January 2.

"Action against miscreants spreading communal hatred on social media underway in a major way. A dedicated team of cyber experts is keeping a hawk's eye on anyone fomenting communal disharmony anywhere on the internet," Harsha said in another tweet.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.